SHL will provide its device development expertise, assembly guidance, and production competencies to support the clinical and potential commercial supply of the sonelokimab project.
Menu
SHL Medical announced today the release of its Sustainability Report for 2022. The report provides a comprehensive overview of the company’s efforts to promote sustainability and outlines its commitment to a sustainable future.
SHL Medical is pleased to announce the appointment of Gwenaël Rouy-Poirier as Chief Financial Officer (CFO) of SHL and a member of the Executive Management Team as of May 2, 2023.
SHL Medical is pleased to announce the appointment of Satbir Bains as Chief Human Resources Officer (CHRO) of SHL and a member of the Executive Management Team as of February 2023.
SHL Medical (hereinafter referred to as “SHL”) has revealed plans for a new manufacturing site in the US, in response to the growing market demand for its autoinjector product portfolio. The decision stems from SHL’s strategic assessments in extending its production to North America.
SHL Medical has announced plans to set up a manufacturing site in Zug, Switzerland to support increasing demands for autoinjector production.
On November 5, SHL Group, a global leader in the design, development, and manufacturing of drug delivery devices, held the inauguration of its new Liufu site in Taoyuan City, Taiwan.
